Tourmaline_logo.jpg
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024 07:30 ET | Tourmaline Bio, Inc.
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Vital Farms Logo.png
Vital Farms Reports Second Quarter 2024 Financial Results and Raises Fiscal Year 2024 Guidance
August 08, 2024 07:20 ET | Vital Farms
Second Quarter Net Revenue of $147.4 million, up 38.5% versus Prior Year PeriodRaises Fiscal Year 2024 Outlook and Reiterates Long-term GuidancePlans for New State-of-the-Art Egg Washing and Packing...
immunocore-logo-2018
Immunocore reports second quarter financial results and provides a business update
August 08, 2024 07:00 ET | Immunocore Holdings plc
KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma ongoing,...
bitfarms.jpg
Bitfarms Reports Second Quarter 2024 Results
August 08, 2024 07:00 ET | Bitfarms Ltd.
- Revenue of $42 million, down 16% Q/Q and up 17% Y/Y - - Gross mining margin of 51%, compared to 64% in Q1 2024 and 48% in Q2 2023 - - Current hashrate of 11.1 EH/s, up from 6.5 EH/s in Q1 2024 --...
Optinose_logo_RGB.png
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
August 08, 2024 07:00 ET | Optinose, Inc.
Company reports Q2 2024 XHANCE net revenue of $20.5 million, an increase of 5% compared to Q2 2023 XHANCE has been added to Express Scripts’ national formularies, among the largest commercial...
Ben Logo.png
Beneficient Announces First Quarter Fiscal 2025 Earnings Release and Webcast
August 08, 2024 07:00 ET | Beneficient
Beneficient announced that it will release its First Quarter Fiscal '25 financial results and webcast after market close on Wednesday, August 14, 2024
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Aveanna healthcare_RGB.jpg
Aveanna Healthcare Holdings Announces Second Quarter 2024 Financial Results and Revised 2024 Outlook
August 08, 2024 06:30 ET | Aveanna Healthcare Holdings, Inc
Second Quarter Revenue was $505.0 million, a 7.0% increase over the prior year Gross margin increased 1.9% to $158.3 million, compared to Q2 2023 Second Quarter Net income was $13.9 million,...
LanzaTech Logo.png
LanzaTech Reports Second-Quarter 2024 Financial Results, Reaffirms Full-Year 2024 Outlook, and Announces $40 Million Capital Raise
August 08, 2024 06:00 ET | LanzaTech Inc.
Achieved total revenue of $17.4 million for second-quarter 2024, exceeding expectations; Reaffirming full-year 2024 outlook
Recursion updates L(
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
August 08, 2024 01:32 ET | Recursion Pharmaceuticals
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates...